Table 3 Clinical features of AH-MGD and AH-non-MGD groups
| Ā | AH-MGD nā=ā8(47%) | AH-non-MGD nā=ā9(53%) | P value |
|---|---|---|---|
Sex ratio (M:F) | 6:2 | 6:3 | 1.000 |
Age (years) | 61.0āĀ±ā8.7 | 56.0āĀ±ā13.3 | 0.391 |
Smoke (n [%]) | 2(25) | 2(22) | 1.000 |
Alcohol abuse (n [%]) | 3(37) | 2(22) | 0.620 |
Family history of tumors (n [%]) | 0 | 3(33) | 0.206 |
BMI (kg/m2) | 24.7āĀ±ā1.5 | 23.0āĀ±ā2.7 | 0.137 |
Choledocholithiasis (n [%]) | 3(37) | 3(33) | 1.000 |
Dilation of the bile ducts (n [%]) | 8(100) | 7(78) | 0.471 |
Cholangitis (n [%]) | 4(50) | 4(44) | 1.000 |
Cancer (n [%]) | 3(37) | 0 | 0.082* |
Laboratory tests Total bilirubin (Āµmol/L) | 18.6(13.5,119.0) | 9.3(7.4,132.1) | 0.336 |
Direct Bilirubin (Āµmol/L) | 4.8(3.6,107.3) | 3.6(1.8,114.6) | 0.470 |
Alkaline phosphatase (U/L) | 150.4(82.4,336.4) | 83.3(64.6,277.9) | 0.290 |
Ī³-glutamyl transpeptidase (U/L) | 127.0(29.8,297.4) | 98.30(23.0,400.5) | 0.630 |
CA19-9 (Āµ/ml) | 13.4(8.8,103.1) | 10.0(6.3,73.4) | 0.336 |